Related Experiment Video
Updated: Jun 5, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Monica A Rojas1, Noel G Carlson, Thomas L Miller
1Neurovirology Research Laboratory, VASLCHCS and Department of Neurology, University of Utah, Salt Lake City, UT, USA.
Therapeutic Advances in Neurological Disorders
|December 25, 2010
Summary
Long-term daclizumab treatment in relapsing-remitting multiple sclerosis (RR MS) patients showed significant benefits. This study found a notable reduction in relapses and improved disability scores, suggesting daclizumab
Area of Science:
- Neurology
- Immunology
- Clinical Therapeutics
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Relapsing-remitting MS (RR MS) is the most common form, characterized by distinct attacks and remissions.
- Long-term treatment options for RR MS are crucial for managing disease progression and patient outcomes.
Purpose of the Study:
- To evaluate the safety and efficacy of long-term daclizumab treatment in patients with RR MS.
- To assess changes in clinical outcomes, including relapse rates and disability progression.
- To determine the tolerability and potential benefits of daclizumab in a real-world clinical setting.
Main Methods:
- Retrospective review of clinical data from twelve RR MS patients.
- Analysis of treatment duration, dosage adjustments, and adverse events.
- Assessment of relapse rates and Expanded Disability Status Scores (EDSS) before and during treatment.
Main Results:
- Daclizumab was generally well-tolerated by RR MS patients.
- A statistically significant reduction in relapse rates was observed (p < 0.0001).
- Significant improvement in Expanded Disability Status Scores (EDSS) was noted, indicating reduced disability.
Conclusions:
- Long-term daclizumab therapy demonstrates apparent clinical benefits for RR MS patients.
- The observed reduction in relapses and improvement in EDSS suggest daclizumab's efficacy.
- Further formal studies are warranted to confirm these promising findings and establish daclizumab's role in RR MS management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...